Cartesian Therapeutics
RNAC
92 hedge funds and large institutions have $79.7M invested in Cartesian Therapeutics in 2022 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 26 increasing their positions, 34 reducing their positions, and 27 closing their positions.
105% more call options, than puts
Call options by funds: $341K | Put options by funds: $166K
11% more capital invested
Capital invested by funds: $71.9M → $79.7M (+$7.77M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.22% less ownership
Funds ownership: 1.55% → 1.33% (-0.22%)
10% less funds holding
Funds holding: 102 → 92 (-10)
24% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 34
30% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$7.18M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$3.46M |
| 3 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$1.15M |
| 4 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$1M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$896K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$4.34M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
-$3.02M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.39M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$1.09M |
| 5 |
Two Sigma Investments
New York
|
-$989K |
RNAC Hedge Fund Activity: Q2 2022 in Review
92 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q2 2022, worth a combined $79.7M — up 11% from $71.9M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of RNAC and 19 opened new positions — a net loss of 8 holders — while 34 trimmed existing stakes and 26 added.
The largest buyer was Mangrove Partners, opening a new position worth an estimated $7.18M. The largest seller was BlackRock, cutting an estimated $4.34M.
- 92 institutional investors held Cartesian Therapeutics (RNAC) as of Q2 2022, down from 102 in Q1 2022.
- Funds reported $79.7M of Cartesian Therapeutics stock for Q2 2022, up 11% quarter-over-quarter.
- 19 funds opened new Cartesian Therapeutics positions in Q2 2022 and 27 closed out, a net change of -8 holders.
- The largest Cartesian Therapeutics buyer in Q2 2022 was Mangrove Partners, an estimated $7.18M added.
- The largest Cartesian Therapeutics seller in Q2 2022 was BlackRock, an estimated $4.34M sold.
Based on aggregated 13F filings for Q2 2022.